Bone Tissue Degenerative Processes Treatment in Germany

Bone tissue degenerative processes (Degenerative Prozesse) are a group of pathological conditions involving progressive destruction, thinning, or structural weakening of bone. Unlike acute fractures, degeneration develops gradually, reducing bone strength and leading to pathological fractures, deformities, and loss of function. Bone degeneration is closely related to osteoporosis, osteonecrosis, and arthrosis. German clinics employ precise bone quality assessment methods, targeted drug therapy, and innovative MIBRAR® therapy to stimulate bone regeneration.

What Are Bone Degenerative Processes

Bone tissue is a living, constantly renewing structure. The bone remodeling cycle: osteoclasts destroy old bone (resorption) → osteoblasts form new bone (formation). In youth, formation predominates over resorption — bone strengthens. After age 30–35, the balance shifts toward resorption — physiological bone mass loss begins (0.5–1% per year). In pathological degenerative processes, the loss accelerates, bone microarchitecture is disrupted, and mineral density decreases.

As noted in Prof. Babayan's book: "Normal regenerative processes and self-renewal constantly occurring in the body slow down with age. Pluripotent stem cells with the participation of growth factors are the most important component of our physical regenerative processes." The MIBRAR® method is based precisely on restoring these processes.

Types

Causes

1. Age-related changes — after age 35, bone resorption begins to predominate over formation. In postmenopausal women, loss accelerates to 2–5% per year (estrogen deficiency).
2. Metabolic disorders — vitamin D and calcium deficiency, hyperparathyroidism, hypogonadism, thyrotoxicosis, diabetes mellitus.
3. Medications — long-term corticosteroid use (glucocorticoid osteoporosis), chemotherapy, antiepileptic drugs, proton pump inhibitors.
4. Disrupted blood supply — avascular necrosis with steroid use, alcoholism, sickle cell anemia.
5. Chronic inflammatory diseases — rheumatoid arthritis, inflammatory bowel diseases — pro-inflammatory cytokines stimulate osteoclasts.
6. Immobilization — loss of loading → bone atrophy. Wolff's law: bone forms along lines of stress.
7. Aseptic implant loosening — wear debris (polyethylene, metal) triggers macrophage reaction → osteolysis around the endoprosthesis.

Symptoms

• Asymptomatic course — the main danger! Osteoporosis and early stages of osteonecrosis are painless. The first manifestation may be a fracture.
• Bone pain — with progressive osteonecrosis, subchondral collapse, pathological fracture. Pain under load, relieved at rest.
• Pathological fractures — fractures with minimal or no trauma (vertebral compression fractures, femoral neck fracture from a standing-height fall).
• Height loss — with multiple vertebral compression fractures — height decrease of 3–5 cm or more.
• Kyphosis ("dowager's hump") — thoracic deformity with vertebral fractures.
• Implant loosening — pain around the endoprosthesis, progressive limping years after arthroplasty.

Diagnostics

1. DEXA densitometry — the gold standard for bone mineral density (BMD) assessment. T-score < -2.5 = osteoporosis. Performed on lumbar spine and femoral neck.
2. X-ray — detection of fractures, deformities, osteolysis around implants. Osteoporosis is visible on X-ray only with > 30% bone mass loss.
3. CT / HRQCT (high-resolution CT) — bone microarchitecture assessment, quantitative CT densitometry, osteolysis visualization.
4. MRI — early diagnosis of osteonecrosis (bone marrow edema — stage 0–1), bone viability assessment.
5. Scintigraphy / SPECT-CT — bone metabolic activity, detection of occult fractures, implant loosening assessment.
6. Laboratory tests — calcium, phosphorus, vitamin D (25-OH), PTH, TSH, testosterone/estradiol; bone turnover markers: osteocalcin, P1NP (formation), CTX, NTX (resorption); ESR, CRP, protein electrophoresis (to rule out multiple myeloma).
7. Bone biopsy — in rare cases with unclear diagnosis (to rule out metastases, myeloma).

Conservative Treatment

• Calcium and vitamin D — baseline therapy. Calcium 1000–1500 mg/day, vitamin D 800–2000 IU/day. Target 25-OH vitamin D level > 30 ng/ml.
• Antiresorptive therapy — bisphosphonates (alendronate, zoledronic acid), denosumab (Prolia). Osteoclast suppression, reduced resorption.
• Anabolic therapy — teriparatide (Forteo), romosozumab (Evenity). Osteoblast stimulation, new bone formation. For severe osteoporosis with fractures.
• Physical therapy — weight-bearing exercises stimulate osteoblasts (Wolff's law). Balance exercises — fall prevention.
• Fall prevention — assessment and correction of fall risk factors (vision, medications, home environment).
• Smoking and alcohol cessation — smoking reduces bone density, alcohol disrupts blood supply and metabolism.

MIBRAR® Therapy

Bone tissue degenerative processes (Degenerative Prozesse) are included in the list of indications for MIBRAR® technology. Professor Babayan's method aims to restore the natural regenerative processes of bone tissue.

Scientific basis (from Prof. Babayan's book): "To stimulate the regenerative process, autologous plasma enriched with growth factors and anti-inflammatory factors, CD34+ stem cells, as well as lipogenic pluripotent mesenchymal stem cells from subcutaneous fat is used." All these components constitute ARK — autologous regenerative concentrate.

MIBRAR® for bone degeneration:

• Osteoblast stimulation — ARK growth factors (BMP, TGF-β, PDGF, VEGF) activate osteoblasts and accelerate new bone formation.
• Angiogenesis stimulation — VEGF and other angiogenic factors in ARK restore blood supply to the affected zone. Critically important in osteonecrosis.
• Stem cell differentiation — ARK mesenchymal stem cells differentiate into osteoblasts, chondrocytes, adipocytes — depending on the microenvironment.
• Anti-inflammatory effect — ARK anti-inflammatory factors suppress chronic inflammation that stimulates osteoclasts.
• MIBRAR® microperforations — targeted micro-injuries to sclerotic or necrotic bone open channels for stem cell migration.

The procedure is outpatient, without anesthesia, guided by Sono Control Arm™ (accuracy 0.1 mm). MIBRAR® procedures cover up to 95% of diagnostic and therapeutic interventions in orthopedics and neurosurgery.

Surgical Treatment

1. Vertebroplasty / kyphoplasty — for osteoporotic vertebral compression fractures. Injection of bone cement into the vertebral body. Immediate pain relief.
2. Core decompression — for early-stage osteonecrosis. Drilling a channel into the necrosis zone to reduce pressure and stimulate angiogenesis.
3. Bone grafting — filling defects with autograft, allograft, or synthetic substitutes (β-tricalcium phosphate, hydroxyapatite).
4. Revision arthroplasty — for osteolysis around a loosened implant. Component replacement + bone grafting of the defect.
5. Joint replacement — for terminal-stage osteonecrosis with joint surface collapse. MIBRAR® may help avoid or postpone this step.

Treatment Cost

All treatment prices in Germany.

Clinics